US Patent Issued to DR. FALK PHARMA on Nov. 4 for "3-(5-chloro-2-oxobenzo[doxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors" (British, French Inventors)

ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,459,906, issued on Nov. 4, was assigned to DR. FALK PHARMA GMBH (Freiburg, Germany).

"3-(5-chloro-2-oxobenzo[doxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors" was invented by Anne Marie Jeanne Bouillot (Les Ulis, France), Olivier Mirguet (Les Ulis, France), John Liddle (Stevenage, Great Britain) and Anne Louise Walker (Stevenage, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "A compound of formula (I) or a salt thereof are provided:wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with syste...